Literature DB >> 27358785

Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience.

Donal B O'Connor1, John P Burke1, John Hegarty1, Aiden P McCormick1, Niamh Nolan1, Emir Hoti1, Donal Maguire1, Justin Geoghegan1, Oscar Traynor1.   

Abstract

AIM: To examine the results of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) in Ireland over a 14-year period.
METHODS: Cases of HCC receiving OLT between January 1995 and September 2009 in the Irish Liver Transplant Unit were reviewed from a prospectively maintained database. Outcome measures included overall and recurrence free survival, alpha-fetoprotein (AFP) and tumour pathological features.
RESULTS: On explant pathology, 57 patients had HCC. The median follow-up time was 42.7 mo. The overall 1, 3 and 5 years survival was 87.7%, 72.1% and 72.4%. There was no difference in survival when compared to patients undergoing OLT without malignancy. The tumour recurrence rate was 14%. The Milan criteria were exceeded in 32% of cases but this did not predict overall survival or recurrence. On multivariate analysis pre-operative AFP > 100 ng/mL was an independent risk factor for recurrence (RR = 5.2, CI: 1.1-24.3, P = 0.036).
CONCLUSION: Patients undergoing OLT for HCC had excellent survival even when conventional listing criteria were exceeded. Pre-operative AFP predicts recurrence independent of tumour size and its role in selection criteria should be investigated in larger studies.

Entities:  

Keywords:  Alpha-fetoprotein; Hepatocellular carcinoma; Liver cirrhosis; Liver transplantation; Transplantation selection criteria

Year:  2016        PMID: 27358785      PMCID: PMC4919744          DOI: 10.5500/wjt.v6.i2.396

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  24 in total

1.  Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.

Authors:  David M Levi; Andreas G Tzakis; Paul Martin; Seigo Nishida; Eddie Island; Jang Moon; Gennaro Selvaggi; Akin Tekin; Beatrice L Madrazo; Govindarajan Narayanan; Monica T Garcia; Lynn G Feun; Panagiotis Tryphonopoulos; Nikolaos Skartsis; Alan S Livingstone
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  MELD score as a prognostic model for listing acute liver failure patients for liver transplantation.

Authors:  M B Zaman; E Hoti; A Qasim; D Maguire; P A McCormick; J E Hegarty; J G Geoghegan; O Traynor
Journal:  Transplant Proc       Date:  2006-09       Impact factor: 1.066

4.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

5.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

6.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25

7.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

8.  Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.

Authors:  Francesco D'Amico; Myron Schwartz; Alessandro Vitale; Parissa Tabrizian; Sasan Roayaie; Swan Thung; Maria Guido; Juan del Rio Martin; Thomas Schiano; Umberto Cillo
Journal:  Liver Transpl       Date:  2009-10       Impact factor: 5.799

9.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

10.  Liver transplantation for hepatocellular carcinoma.

Authors:  R Selby; Z Kadry; B Carr; A Tzakis; J R Madariaga; S Iwatsuki
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  2 in total

1.  Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.

Authors:  Vladimir J Lozanovski; Ali Ramouz; Ehsan Aminizadeh; Sadeq Ali-Hasan Al-Saegh; Elias Khajeh; Heike Probst; Susanne Picardi; Christian Rupp; De-Hua Chang; Pascal Probst; Arianeb Mehrabi
Journal:  BJS Open       Date:  2022-01-06

Review 2.  Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Maria J Citores; Jose L Lucena; Sara de la Fuente; Valentin Cuervas-Mons
Journal:  World J Hepatol       Date:  2019-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.